Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Total Current Liabilities
All obligations due within one year.
Immunic, Inc.NASDAQ: IMUX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 49.9% from a year ago
Total current liabilities stood at $38.36M at the end of Q1 FY2026, up 49.9% from a year earlier and up 25.3% from the prior quarter. Over 3 fiscal years it compounded at +32.8% a year.
Context
- Total current liabilities amounted to 20.2% of total assets at the end of Q1 FY2026, down 104.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +49.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 30.62M USD
- Year-over-year change
- +38.1%
- 4-year CAGR
- +28.0%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.62M | +38.1% |
| FY2024 | 2024-12-31 | 22.18M | -10.3% |
| FY2023 | 2023-12-31 | 24.73M | +89.1% |
| FY2022 | 2022-12-31 | 13.08M | +14.7% |
| FY2021 | 2021-12-31 | 11.4M | — |
Total Current Liabilities vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's Mar 2026 total current liabilities of $38.36M is the 2nd highest of the 9 companies compared; the peer median is $13.42M.
- Its year-over-year change of +49.9% is the 2nd highest of 9, against a peer median of -20.2%.
- Total current liabilities amounts to 20.2% of total assets for IMUX, versus a peer median of 10.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76.84M | -22.0% | +69.2% | 42.7% | |
| Mar 2026 | $38.36M | +49.9% | +32.8% | 20.2% | |
| Mar 2026 | $19.97M | -33.0% | +2.6% | 9.9% | |
| Mar 2026 | $18.3M | +11.3% | +3.0% | 10.8% | |
CBUSCibus, Inc. | Mar 2026 | $13.94M | -33.6% | +116.5% | 4.3% |
| Mar 2026 | $12.89M | +146.4% | -19.8% | 5.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $11.05M | -18.4% | +34.0% | 10.3% |
| Mar 2026 | $9.29M | -53.1% | -16.5% | 20.0% | |
| Mar 2026 | $8.6M | -11.9% | +1.8% | 8.9% | |
| Peer median (excluding IMUX) | $13.42M | -20.2% | +2.8% | 10.1% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.86M | 106.75M | 46.67M | 35.67M | 15.48M |
| Short-term Investments | 0 | 9.63M | 0 | 0 | 0 |
| Net Receivables | 2.15M | 296K | 703K | 684K | 4.12M |
| Inventory | 0 | 5.61M | 0 | 0 | 0 |
| Other Current Assets | 1.12M | 3.59M | 2.84M | 1.11M | 1.2M |
| Total Current Assets | 104.99M | 125.86M | 52.53M | 39.33M | 22.87M |
| Property, Plant & Equipment (Net) | 1.1M | 1.85M | 1.77M | 1.54M | 1.18M |
| Goodwill | 32.97M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 42K | 43K | 0 | 0 | 0 |
| Total Non-current Assets | 34.11M | 1.89M | 1.77M | 1.54M | 1.18M |
| Total Assets | 139.1M | 127.75M | 54.3M | 40.87M | 24.05M |
| Account Payables | 3.5M | 4.28M | 5.1M | 7.85M | 10.14M |
| Short-term Debt | 0 | 0 | 0 | 0 | 470K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 851K | 7.34M | 17.48M | 676K | 20.01M |
| Total Current Liabilities | 11.4M | 13.08M | 24.73M | 22.18M | 30.62M |
| Long-term Debt | 0 | 0 | 0 | 0 | 107K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (107K) |
| Total Non-current Liabilities | 584K | 992K | 639K | 264K | 107K |
| Total Liabilities | 11.99M | 14.07M | 25.37M | 22.44M | 30.73M |
| Common Stock | 3K | 4K | 4K | 8K | 9K |
| Retained Earnings | (196.87M) | (317.28M) | (410.89M) | (511.4M) | (608.57M) |
| Accumulated OCI | (252K) | 3.04M | 3.76M | 4.21M | 2.65M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 127.12M | 113.68M | 28.93M | 18.43M | (6.67M) |
| Total Debt | 992K | 1.56M | 1.33M | 1M | 684K |
| Net Debt | (85.87M) | (105.18M) | (45.34M) | (34.66M) | (14.8M) |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.